{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T12:56:34Z","timestamp":1761310594858},"reference-count":124,"publisher":"Informa UK Limited","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Future Med. Chem."],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.4155\/fmc.09.88","type":"journal-article","created":{"date-parts":[[2009,11,13]],"date-time":"2009-11-13T11:44:15Z","timestamp":1258112655000},"page":"1429-1452","source":"Crossref","is-referenced-by-count":24,"title":["Nucleoside Analog Inhibitors of Hepatitis C Viral Replication: Recent Advances, Challenges and Trends"],"prefix":"10.1080","volume":"1","author":[{"given":"Phillip A","family":"Furman","sequence":"first","affiliation":[{"name":"Pharmasset, Inc.\r303A College Road East, Princeton, NJ08540, USA"}]},{"given":"Angela M","family":"Lam","sequence":"additional","affiliation":[{"name":"Pharmasset, Inc.\r303A College Road East, Princeton, NJ08540, USA"}]},{"given":"Eisuke","family":"Murakami","sequence":"additional","affiliation":[{"name":"Pharmasset, Inc.\r303A College Road East, Princeton, NJ08540, USA"}]}],"member":"301","published-online":{"date-parts":[[2009,11,13]]},"reference":[{"key":"e_1_3_3_2_1_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1521-6918(03)00014-3"},{"key":"e_1_3_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811193392101"},{"key":"e_1_3_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"e_1_3_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.23.13034"},{"key":"e_1_3_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/13305"},{"key":"e_1_3_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0969-2126(00)80031-3"},{"key":"e_1_3_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.7.3482-3492.2002"},{"key":"e_1_3_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2836(02)01439-0"},{"key":"e_1_3_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.13.7575-7581.2003"},{"key":"e_1_3_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M209397200"},{"key":"e_1_3_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M413410200"},{"key":"e_1_3_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M410191200"},{"key":"e_1_3_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-6-255"},{"key":"e_1_3_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.23.13278-13284.2004"},{"key":"e_1_3_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.24.13225-13231.2003"},{"key":"e_1_3_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2006.05.074"},{"key":"e_1_3_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M505423200"},{"key":"e_1_3_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh319"},{"key":"e_1_3_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.2174\/187152606776056724"},{"key":"e_1_3_3_2_20_1","first-page":"614","article-title":"Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections.","volume":"8","author":"Beaulieu PL","year":"2007","unstructured":"Beaulieu PL . Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections.Curr. Opin. Investig. Drugs.8, 614\u2013634 (2007).","journal-title":"Curr. Opin. Investig. Drugs."},{"key":"e_1_3_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20819"},{"key":"e_1_3_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.14.7352-7359.2004"},{"key":"e_1_3_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.5.2059-2069.2005"},{"key":"e_1_3_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi051565g"},{"key":"e_1_3_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2007.04.016"},{"key":"e_1_3_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00533-08"},{"key":"e_1_3_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2008.11.002"},{"key":"e_1_3_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2007.10.006"},{"key":"e_1_3_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21781"},{"key":"e_1_3_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-009-0003-9"},{"key":"e_1_3_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v13.i43.5673"},{"key":"e_1_3_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2008.09.007"},{"key":"e_1_3_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.08.002"},{"key":"e_1_3_3_2_34_1","doi-asserted-by":"crossref","unstructured":"Dusheiko G HezodeC PolSet al. Treatment of chronic hepatitis C with telaprevir in combination with peginterferon A-2a with or without ribavirin: interim results of the PROVE2 study. Presented at: 43rd Meeting of the European Association for the Study of the Liver. Milan Italy 23\u201327 April 2008.","DOI":"10.1016\/S0016-5085(08)63525-8"},{"key":"e_1_3_3_2_35_1","doi-asserted-by":"crossref","unstructured":"McHutchison JG EversonG GordonSCet al. PROVE1: results from a Phase 2 study of telaprevir with peginterferon \u03b1-2a and ribavirin in treatment-naive subjects with hepatitis C. Presented at: 43rd Meeting of the European Association for the Study of the Liver. Milan Italy 23\u201327 April 2008.","DOI":"10.1016\/S0168-8278(08)60006-9"},{"key":"e_1_3_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(07)62381-2"},{"key":"e_1_3_3_2_37_1","unstructured":"Afdahl N GodofskyE DienstagJet al. Final Phase I\/II trial results for NM283 a new polymerase inhibitor for hepatitis C: antiviral efficacy and tolerance in patients with HCV-1 infection including previous interferon failures. Presented at: 55th Annual Meeting of the American Association for the Study of Liver Diseases. Boston MA USA 29 October\u20132 November 2004."},{"key":"e_1_3_3_2_38_1","doi-asserted-by":"crossref","unstructured":"Nelson D PockorsP GodofskyEet al. High end-of-treatment response (84%) after 4 weeks of R1626 peginterferon \u03b1-2A (40 kDa) and ribavirin followed by a further 44 weeks of peginterferon \u03b1-2A and ribavirin. Presented at: 43rd Annual Meeting of the European Association for the Study of the Liver. 2008. Milan Italy.","DOI":"10.1016\/S0168-8278(08)60995-2"},{"key":"e_1_3_3_2_39_1","first-page":"838","article-title":"Inhibitors of the HCV NS5B polymerase: new hope for the treatment of hepatitis C infections.","volume":"5","author":"Beaulieu PL","year":"2004","unstructured":"Beaulieu PL , TsantrizosYS. Inhibitors of the HCV NS5B polymerase: new hope for the treatment of hepatitis C infections.Curr. Opin. Investig. Drug5, 838\u2013850 (2004).","journal-title":"Curr. Opin. Investig. Drug"},{"key":"e_1_3_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.2174\/187152606776056698"},{"key":"e_1_3_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn085"},{"key":"e_1_3_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01317-07"},{"key":"e_1_3_3_2_43_1","doi-asserted-by":"crossref","unstructured":"Le Pogam S SeshaadriA KangHet al. Low level of resistance and low viral fitness in vitro and absence of resistance mutations in baseline quasispecies may contribut to high barrier to R1626 resistance in vivo. Presented at: 3rd International Workshop on Hepatitis C \u2013 Resistance and New Compounds. Boston MA USA 5\u20136 June 2008.","DOI":"10.1016\/S0168-8278(08)60023-9"},{"key":"e_1_3_3_2_44_1","unstructured":"Le Pogam S SeshaadriA KosakaAet al. Lack of R7128 resistance in vivo may contribute to its potent antiviral activity in genotype 1 non-responder HCV patients. Presented at: 3rd International Workshop on Hepatitis C \u2013 Resistance and New Compounds. Boston MA USA 5\u20136 June 2008."},{"key":"e_1_3_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.75.10.4798"},{"key":"e_1_3_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(89)92105-0"},{"key":"e_1_3_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M210914200"},{"key":"e_1_3_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M305041200"},{"key":"e_1_3_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.5.2050-2058.2005"},{"key":"e_1_3_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm030424e"},{"key":"e_1_3_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm040068f"},{"key":"e_1_3_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.10.3944-3953.2004"},{"key":"e_1_3_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01032-08"},{"key":"e_1_3_3_2_54_1","unstructured":"Tauzin B . Pharmaceutical research continues against infectious diseases with 388 medicinees and vaccines in testing. In: Medicines in Development for Infectious Diseases. PhrMA DC USA 1\u201336 (2007)."},{"key":"e_1_3_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2007.05.020"},{"key":"e_1_3_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm0603623"},{"key":"e_1_3_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01184-07"},{"key":"e_1_3_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00400-06"},{"key":"e_1_3_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2007.0199"},{"key":"e_1_3_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.2.651-654.2004"},{"key":"e_1_3_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1177\/095632020601700203"},{"key":"e_1_3_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm0502788"},{"key":"e_1_3_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M705274200"},{"key":"e_1_3_3_2_64_1","doi-asserted-by":"crossref","unstructured":"Cretton-Scott E PerigaudC PeyrottesSet al. In vitro antiviral activity and pharmacology of IDX184 a novel and potent inhibitor of HCV replication. Presented at: 43rd Meeting of the European Association for the Study of the Liver. Milan Italy 23\u201327 April 2008.","DOI":"10.1016\/S0168-8278(08)60590-5"},{"key":"e_1_3_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2005.12.002"},{"key":"e_1_3_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1093\/nass\/nrn325"},{"key":"e_1_3_3_2_67_1","doi-asserted-by":"crossref","unstructured":"Standring DN LanfordR Cretton-ScottEet al. Potent antiviral activity of second generation nucleoside inhibitors IDX102 and IDX184 in HCV-infected chimpanzees. Presented at: 43rd Meeting of the European Association for the Study of the Liver. Milan Italy 23\u201327 April 2008.","DOI":"10.1016\/S0168-8278(08)60069-0"},{"key":"e_1_3_3_2_68_1","unstructured":"Gane E Rodriguez-TorresM NelsonDet al. Antiviral activity of the HCV nucleoside polymerase inhibitor R7128 in HCV genotype 2 and 3 prior non-responders: results of R7128 1500mg BID with PEG-IFN and ribavirin for 28 days. Presented at: 59th Annual Meeting of the American Association for the Study of Liver Diseases. San Francisco CA USA 31 October\u20134 November 2008."},{"key":"e_1_3_3_2_69_1","doi-asserted-by":"crossref","unstructured":"Tan H SonalR WuTet al. Combination of the NS3\/4A protease inhibitor ITMN-191 (R7227) with the active moiety of the NS5B inhibitors R1626 or R7128 enhances replicon clearance and reduces the emergence of drug resistant variants. Presented at: 59th Annual Meeting of the American Association for the Study of Liver Diseases. San Francisco CA USA 31 October\u20134 November 2008.","DOI":"10.1016\/S0168-8278(09)60938-7"},{"key":"e_1_3_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M510195200"},{"key":"e_1_3_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22321"},{"key":"e_1_3_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M708929200"},{"key":"e_1_3_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm800981y"},{"key":"e_1_3_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm801595c"},{"key":"e_1_3_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2004.12.011"},{"key":"e_1_3_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.12.4636-4642.2004"},{"key":"e_1_3_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1177\/095632020401500105"},{"key":"e_1_3_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm0401210"},{"key":"e_1_3_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.1081\/NCN-200059314"},{"key":"e_1_3_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1080\/15257770500265802"},{"key":"e_1_3_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1081\/NCN-200059319"},{"key":"e_1_3_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.1080\/15257770601052307"},{"key":"e_1_3_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tetlet.2005.02.120"},{"key":"e_1_3_3_2_84_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm050335x"},{"key":"e_1_3_3_2_85_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm0495172"},{"key":"e_1_3_3_2_86_1","unstructured":"Furman PA BaoD ChangWet al. \u03b2-D-2\u00b4-deoxy-2\u00b4-fluoro-2\u00b4-C-methyluridine phosphoramidates are potent and selective inhibitors of HCV RNA replication. Presented at: 15th International Symposium on Hepatitis C Virus And Related Viruses. San Antonio TX USA 5\u20139 October 2008."},{"key":"e_1_3_3_2_87_1","unstructured":"Sofia MA WangP DuJet al. \u03b2-D-2\u00b4-deoxy-2\u00b4-fluoro-2\u00b4-C-methyluridine phosphoramidates: potent and selective inhibitors of HCV RNA replication. Presented at: 14th International Symposium on Hepatitis C Virus and Related Viruses. Glasgow Scotland UK 9\u201313 October 2007."},{"key":"e_1_3_3_2_88_1","unstructured":"Sofia MA WangP DuJet al. \u03b2-D-2\u00b4-deoxy-2\u00b4-fluoro-2\u00b4-C-methyluridine (PSI-6206) phosphoramidates: potent liver targeting nucleoside inhibitors of HCV RNA replication. Presented at: 236th ACS National Meeting. Philadelphia PA USA 18 August 2008."},{"key":"e_1_3_3_2_89_1","unstructured":"Furman PA WangP NiuCet al. PSI-7851: a novel liver-targeting nucleotide prodrug for the treatment of hepatitis C. Presented at: 59th Annual Meeting of the American Association for the Study of Liver Diseases. San Francisco CA USA 31 October\u20134 November 2008."},{"key":"e_1_3_3_2_90_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm070362i"},{"key":"e_1_3_3_2_91_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm0613370"},{"key":"e_1_3_3_2_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2009.01.035"},{"key":"e_1_3_3_2_93_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm950605j"},{"key":"e_1_3_3_2_94_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm0701021"},{"key":"e_1_3_3_2_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2007.02.030"},{"key":"e_1_3_3_2_96_1","unstructured":"Lallos L La CollaM SoubasakosMAet al. Enhanced antiviral activity of IDX184 in combination with IFN-\u03b1 RBV or an IDX PI in the HCV replicon model. Presented at: 15th International Symposium on Hepatitis C Virus and Related Viruses. San Antonio TX USA 5\u20139 October 2008."},{"key":"e_1_3_3_2_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2006.03.045"},{"key":"e_1_3_3_2_98_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00444-08"},{"key":"e_1_3_3_2_99_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00433-06"},{"key":"e_1_3_3_2_100_1","unstructured":"Uzgiris A SteuerHM EurakamiEet al. High genetic barrier to HCV resistance presented by PSI-6130. Presented at: HepDart: Frontiers in Drug Development for Viral Hepatitis. Lahaina Hawaii 9\u201311 December 2007."},{"key":"e_1_3_3_2_101_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22549"},{"key":"e_1_3_3_2_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1089-3261(05)70234-8"},{"key":"e_1_3_3_2_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(05)00711-1"},{"key":"e_1_3_3_2_104_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v13.i36.4808"},{"key":"e_1_3_3_2_105_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v13.i17.2461"},{"key":"e_1_3_3_2_106_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v13.i17.2416"},{"key":"e_1_3_3_2_107_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01543-06"},{"key":"e_1_3_3_2_108_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01496-07"},{"key":"e_1_3_3_2_109_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.076646"},{"key":"e_1_3_3_2_110_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2411"},{"key":"e_1_3_3_2_111_1","unstructured":"Lam AM EspirituC SteuerHMet al. PSI-6130 is synergisitic or additive in combination with HCV protease or polymerase inhibitors in subgenomic replicons. Presented at: 15th International Symposium on Hepatitis C Virus and Related Viruses. San Antonio TX USA 5\u20139 October 2008."},{"key":"e_1_3_3_2_112_1","unstructured":"Stella VJ BorchardtRT HagemanMJ OliyaiR MaagH TilleyJ. Prodrugs: Challenges and Rewards. Stella VJ (Ed.). Springer NY USA (2007)."},{"key":"e_1_3_3_2_113_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja031818y"},{"key":"e_1_3_3_2_114_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.104.075903"},{"key":"e_1_3_3_2_115_1","first-page":"109","article-title":"HepDirect prodrugs for targeting nucleotide-based antiviral drugs to the liver.","volume":"7","author":"Erion MD","year":"2006","unstructured":"Erion MD , BulloughDA, LinCC, HongZ. HepDirect prodrugs for targeting nucleotide-based antiviral drugs to the liver.Curr. Opin. Investig. Drugs.7, 109\u2013117 (2006).","journal-title":"Curr. Opin. Investig. Drugs."},{"key":"e_1_3_3_2_116_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2005.03.106"},{"key":"e_1_3_3_3_2_1","unstructured":"HCV-796 Dosing Discontinued www.hcvadvocate.org\/news\/newsLetter\/2007\/advocate0907.html#2"},{"key":"e_1_3_3_3_3_1","unstructured":"R7128 a prodrug of PSI-6130 www.pharmasset.com\/pipeline\/R7128.asp"},{"key":"e_1_3_3_3_4_1","unstructured":"Pharmasset presents results of 4-week combination study of R7128 for the treatment of chronic hepatitis C http:\/\/investor.pharmasset.com\/releasedetail.cfm?ReleaseID=306746"},{"key":"e_1_3_3_3_5_1","unstructured":"Pharmasset reports preliminary results of a 4-week combination study of R7128 for the treatment of chronic hepatitis C http:\/\/investor.pharmasset.com\/releasedetail.cfm?ReleaseID=326273"},{"key":"e_1_3_3_3_6_1","unstructured":"Roche InterMune and Pharmasset announce initiation of INFORM-1 the first dual-combination clinical trial with oral anti-virals in hepatitis C http:\/\/investor.pharmasset.com\/releasedetail.cfm?ReleaseID=346556."},{"key":"e_1_3_3_3_7_1","unstructured":"Ground-breaking combination of all-oral agents demonstrates potential as hepatitis C treatment regimen http:\/\/investor.pharmasset.com\/releasedetail.cfm?ReleaseID=379753"},{"key":"e_1_3_3_3_8_1","unstructured":"Pharmasset and Roche obtain FDA consent to start a Phase 2b study with R7128 in treatment naive HCV patients http:\/\/investor.pharmasset.com\/releasedetail.cfm?ReleaseID=358626"},{"key":"e_1_3_3_3_9_1","unstructured":"Pharmasset initiates Phase 1b multiple ascending dose clinical trial of PSI-7851 in chronic hepatitis C patients http:\/\/investor.pharmasset.com\/releasedetail.cfm?ReleaseID=388689"}],"container-title":["Future Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.4155\/fmc.09.88","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T19:49:45Z","timestamp":1716493785000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.4155\/fmc.09.88"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":124,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["10.4155\/fmc.09.88"],"URL":"https:\/\/doi.org\/10.4155\/fmc.09.88","relation":{},"ISSN":["1756-8919","1756-8927"],"issn-type":[{"value":"1756-8919","type":"print"},{"value":"1756-8927","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}